

Special Issue

Potential Medical Treatments of Abdominal Aortic Aneurysms

Message from the Guest Editors

An abdominal aortic aneurysm (AAA) refers to localized enlargement of the aorta. Globally, AAA rupture is a major cause of death, being responsible for the death of 1% of men above the age of 65 years. Today, patients with known AAAs are monitored, and will be offered surgical repair when the AAA diameter is above 5–6 cm. Thus, there is an urgent unmet clinical need for medical therapies for small AAAs, to prevent progressive dilatation, acute or elective surgical repair, rupture, and deaths. This Special Issue aims to provide novel insights into the pathogenesis of AAA, with therapeutic possibilities, identifying potential new biomarkers, enabling clinicians to follow AAA expansion and the potential need for surgical repair, possibly by using a translational approach. There is a need to identify novel therapeutic targets of AAA progression, potentially involving vaccines, gene therapies, cell-based therapies, targeted specific antibodies, or recombinant therapeutic proteins. Furthermore, there is a need to develop new delivery systems, directed to reach and work at the site of the aneurysm, using nanobiotechnology.

Guest Editors

Dr. Jane Stubbe

Cardiovascular and Renal Research Unit, Institute for Molecular Medicine, University of Southern Denmark, 5000 Odense, Denmark

Prof. Dr. Jes Sanddal Lindholt

1. The Research Unit of Cardiac, Thoracic and Vascular Surgery, Odense University Hospital, 5000 Odense, Denmark
2. Department of Clinical Research, University of Southern Denmark, 5000 Odense, Denmark

Deadline for manuscript submissions

closed (15 December 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/117331

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).